Compare Regeneron Pharmaceuticals Inc (REGN) vs Tempus AI (TEM) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.

Tempus AI (TEM) trades at $48.41, down 7.74% amid market reaction to its $1.5 billion acquisition of Personalis. The stock shows bearish technical signals with negative moving averages and oversold RSI levels. Fundamentally, the company maintains strong revenue growth ($1.27B in 2025) but faces significant losses (-$245M net income) and negative margins. Recent news highlights strategic expansion in cancer diagnostics through AI-driven platforms.

Despite analyst optimism (61.5% buy ratings, $68.50 target), TEM faces execution risks from the major acquisition and persistent profitability challenges. The stock's current discount to target offers potential upside if integration succeeds, but high cash burn and competitive pressures require careful monitoring for investors considering entry at these levels.